Our pipeline
Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next expected event
Next Gen viruses
-
Novel mutRAS concepts
-
Cancer Indication:
Mesothelioma
Combination with: Combination w/
pemetrexed/cisplatin
Product candidate: ONCOS-102
Next expected event: 2H21 Survival update
Combination with: Combination w/
pemetrexed/cisplatin
Product candidate: ONCOS-102
Next expected event: 2H21 Survival update
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Melanoma
Combination with: Combination w/Keytruda
Product candidate: ONCOS-102
Next expected event: 2022 First patient
Combination with: Combination w/Keytruda
Product candidate: ONCOS-102
Next expected event: 2022 First patient
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Colorectal
Combination with: Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
Product candidate: ONCOS-102
Next expected event: 1H22 Clinical data
Combination with: Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
Product candidate: ONCOS-102
Next expected event: 1H22 Clinical data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: -
Product candidate: Next Gen viruses
Next expected event: Updates at conferences
Combination with: -
Product candidate: Next Gen viruses
Next expected event: Updates at conferences
Discovery
Preclinical
Phase 1
Phase 2
Phase 3